An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

Inclusion Criteria

• •MGD Patients:
• •* Evidence of meibomian gland obstruction (based on a meibomian gland secretion (MGS) score of ≤12 for 15 glands of the lower lid) in both eyes at the baseline visit
• •* Reported dry eye signs and symptoms within the past 3 months
• •* TBUT \< 10 seconds in both eyes
• •CLD Patients:
• •* Evidence of meibomian gland obstruction (based on a meibomian gland secretion (MGS) score of ≤12 for 15 glands of the lower lid) in both eyes at the baseline visit
• •* A history of wearing soft contact lenses for at least 6 months
• •* Wearing of the soft contact lenses for at least 3 weeks before the baseline visit and wore or attempted to wear lenses at least 4 times a week before the baseline visit.
• •* Symptomatic as defined by an answer of "No" at baseline to the question, "Are you able to comfortably wear your lenses as long as you want?"
• •* Self-reported history of contact lens dryness/intolerance in the 6 months preceding the baseline visit.
• •* Baseline CLDEQ-8 score \>12
• •* Contact lens may be use during the study as long as they are removed 15 minutes before dosing and not reinserted until at least 15 minutes after dosing.